UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Read More
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Read More
Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management
Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.
Read More
Treatment Strategies for Uncommon EGFR Mutations in NSCLC
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Read More
Navigating Uncommon EGFR Mutations in NSCLC: Challenges and Insights
Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.
Read More
Standard-of-Care Approaches in EGFR-Mutant NSCLC
Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.
Read More
Navigating Uncommon Mutations in NSCLC Treatment Decisions
The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.
Read More
Non–Small Cell Lung Cancer: Streamlining Turnaround Times in Biomarker Testing
Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.
Read More
Available Methods for Biomarker Testing in Non–Small Cell Lung Cancer
Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.
Read More
Advancement in NSCLC Precision Medicine: Biomarker Testing
Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.
Read More
Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Read More
Emerging Targets in Non–Small Cell Lung Cancer
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Read More
Approach to Treating Patients with NSCLC and RET Fusions
Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.
Read More
Treatment of NTRK Fusions in NSCLC
Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.
Read More
Choosing Between ALK Inhibitors in the Treatment of NSCLC
The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.
Read More
Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Read More
Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.
Read More
Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC
Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.
Read More
NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy
Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.
Read More
Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations
Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.
Read More
Treatment Options for Patients with NSCLC with EGFR Mutations
Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.
Read More
Strategies to Improve Biomarker Testing in NSCLC
Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.
Read More
Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC
Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.
Read More
NSCLC: Biomarker Testing Strategies and Turnaround Time
Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.
Read More
Liquid vs Tissue Biopsies in NSCLC
Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.
Read More
Biomarker Testing in Non-Small Cell Lung Cancer
A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.
Read More